CardiomyopathyCardiac hemochromatosis: Beneficial effects of iron removal therapy: An echocardiographic study
References (33)
- et al.
Iron in the heart. Etiology and clinical significance
Am J Med
(1971) - et al.
Cardiac hemochromatosis simulating constrictive pericarditis
Am J Med
(1962) - et al.
Hemochromatosis heart disease: an unemphasized cause of potentially reversible restrictive cardiomyopathy
Am J Med
(1980) - et al.
Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition
Am J Med
(1978) - et al.
Echocardiographic observations in patients with systemic infiltrative disease involving the heart
Am J Cardiol
(1977) - et al.
Massive myocardial hemosiderosis: a structure-function conference at the National Heart and Lung Institute
Am Heart J
(1975) - et al.
Left ventricular function in gb-thalassemia and the effect of multiple transfusions
Am Heart J
(1978) - et al.
Echocardiographic manifestations of infiltrative cardiomyopathy. A report of seven cases due to amyloid
Chest
(1976) - et al.
Increased right ventricular wall thickness on echocardiography in amyloid infiltrative cardiomyopathy
Am J Cardiol
(1979) - et al.
Myocardial texture characterization by two-dimensional echocardiography
Am J Cardiol
(1983)
The reversal of hemochromatotic cirrhosis by multiple phlebotomies: report of a case
Gastroenterology
The treatment of hemochromatosis by phlebotomy
Med Clin North Am
Hemochromatosis
Hemochromatosis presenting as congestive cardiomyopathy and responding to venesection
Br Heart J
La myocardiophatie de l'hémochromatose idiopatique
Arch Mal Coeur
La myocardiopathie hémochromatosique: role bénéfique de la déplétion ferrique
Ann Cardiol
Cited by (60)
Iron effects versus metabolic alterations in hereditary hemochromatosis driven bone loss
2022, Trends in Endocrinology and MetabolismCitation Excerpt :Besides liver cirrhosis, cardiac dysfunction is the second major cause of death of patients with HH [101,102]. Phlebotomy improves cardiomyopathy, suggesting that this pathology is iron-driven [102–104]. Even though a potential association of cardiac dysfunction and osteoporosis has not yet been documented in HH, given the shared risk factors and their high prevalence in HH, future investigations into a potential interdependence of these two diseases might provide deeper insights into the pathogenesis of osteoporosis in HFE-HH.
Primary Restrictive, Infiltrative, and Storage Cardiomyopathies
2020, Diastology: Clinical Approach to Heart Failure with Preserved Ejection FractionEchocardiography in Infiltrative Cardiomyopathy
2019, Heart Lung and CirculationCitation Excerpt :Whilst CMR is the gold standard for non-invasive imaging in patients with or with suspected IOC due to its ability to determine myocardial iron content; echocardiography is a valuable tool for screening and follow-up of these patients. Patients may present with different phenotypes depending of the degree of iron overload which may include diastolic dysfunction, increased LV wall thickness, dilated cardiomyopathy and/or restrictive cardiomyopathy [86,87]. Both speckle tracking strain and TDI have demonstrated regional systolic LV and RV abnormalities in patients with IOC due to beta thalassaemia [88].
Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 2 of a 2-Part Series
2018, Journal of the American College of CardiologyCitation Excerpt :After the therapeutic levels have been achieved, maintenance phlebotomy is undertaken to maintain a serum ferritin <100 mg/ml and transferrin saturation <50% (68). Improvements in cardiac function with RCM and arrhythmias have been noted if aggressive iron removal is initiated early in the disease process (69,70). Chelation therapy has been shown to be effective as an alternative option when phlebotomy is not feasible for patients who have IOC and chronic anemia or malignancy.
Cardiomyopathies
2012, Principles of Echocardiography and Intracardiac Echocardiography